Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving Surgery
ABSTRACT Purpose The objective of this study was retrospectively to compare the efficacy and safety of hypofractionated radiotherapy (HFRT) with a simultaneous integrated boost (SIB) or with a sequential boost (SB) after breast‐conserving surgery in patients diagnosed with early breast cancer. Metho...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70630 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850200562841157632 |
|---|---|
| author | Na Li Yang Zhou Jianting Wang Yuwei Wang Ruiyu Shao Haifang Yang Wei Xiong Xuan Zheng Xiaohong Wang |
| author_facet | Na Li Yang Zhou Jianting Wang Yuwei Wang Ruiyu Shao Haifang Yang Wei Xiong Xuan Zheng Xiaohong Wang |
| author_sort | Na Li |
| collection | DOAJ |
| description | ABSTRACT Purpose The objective of this study was retrospectively to compare the efficacy and safety of hypofractionated radiotherapy (HFRT) with a simultaneous integrated boost (SIB) or with a sequential boost (SB) after breast‐conserving surgery in patients diagnosed with early breast cancer. Methods This study enrolled a total of 343 patients diagnosed with T1‐2N0‐1 breast cancer who had undergone breast‐conserving surgery followed by whole‐breast irradiation (WBI) without nodal irradiation, between March 2018 and April 2021. Out of 343 patients, 176 (51.3%) received HFRT‐SIB treatment, totaling 15 sessions, while the remaining 167 (48.7%) received HFRT‐SB treatment, totaling 18 sessions. Demographic characteristics, skin toxicity, radiation pneumonia, and myelosuppression, were compared in the two groups. Three‐year local progression free survival (LPFS) rates were determined using the Kaplan–Meier method and compared using the log‐rank test. Results The median follow‐up time was 39.7 months (range 24.3–61.3 months). Toxicities rates did not differ significantly in the HFRT‐SIB and HFRT‐SB groups, including rates of grade 2 skin toxicity (14.8% vs. 13.8%, p = 0.721), Grade 2 radiation pneumonia (2.8% vs. 3.6%, p = 0.355), grades 1, 2 and 3 myelosuppression (12.5%, 5.7% and 1.1%, respectively, vs. 9.6%, 7.8%, and 1.2%, respectively; p = 0.744). Three‐year cumulative LPFS rates were similar in the HFRT‐SIB and HFRT‐SB groups (99.3% vs. 98.6%, p = 0.52). Regional nodal recurrences were observed in one patient in the HFRT‐SIB group (after 27.4 months) and in two patients in the HFRT‐SB group (after 29.4 and 56.4 months), and a local recurrence was observed in one patient in the latter group after 36.0 months. One patient in the HFRT‐SIB group was diagnosed with distant metastases to bone, and one patient in the HFRT‐SB group was diagnosed with distant metastases to the liver. Conclusion Similar efficacy and safety of HFRT‐SIB and HFRT‐SB after breast‐conserving surgery in patients with early‐stage (T1‐2N0‐1) breast cancer. Longer‐term follow‐up is required to further compare their efficacy. |
| format | Article |
| id | doaj-art-36f54b2d8be643e4beb74e19e8875ee4 |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-36f54b2d8be643e4beb74e19e8875ee42025-08-20T02:12:19ZengWileyCancer Medicine2045-76342025-03-01146n/an/a10.1002/cam4.70630Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving SurgeryNa Li0Yang Zhou1Jianting Wang2Yuwei Wang3Ruiyu Shao4Haifang Yang5Wei Xiong6Xuan Zheng7Xiaohong Wang8Tangshan People's Hospital Tangshan Hebei ChinaTangshan People's Hospital Tangshan Hebei ChinaTangshan People's Hospital Tangshan Hebei ChinaTangshan People's Hospital Tangshan Hebei ChinaTangshan People's Hospital Tangshan Hebei ChinaTangshan People's Hospital Tangshan Hebei ChinaTangshan People's Hospital Tangshan Hebei ChinaTangshan People's Hospital Tangshan Hebei ChinaDepartment of Radiochemotherapy Tangshan People's Hospital Tangshan Hebei ChinaABSTRACT Purpose The objective of this study was retrospectively to compare the efficacy and safety of hypofractionated radiotherapy (HFRT) with a simultaneous integrated boost (SIB) or with a sequential boost (SB) after breast‐conserving surgery in patients diagnosed with early breast cancer. Methods This study enrolled a total of 343 patients diagnosed with T1‐2N0‐1 breast cancer who had undergone breast‐conserving surgery followed by whole‐breast irradiation (WBI) without nodal irradiation, between March 2018 and April 2021. Out of 343 patients, 176 (51.3%) received HFRT‐SIB treatment, totaling 15 sessions, while the remaining 167 (48.7%) received HFRT‐SB treatment, totaling 18 sessions. Demographic characteristics, skin toxicity, radiation pneumonia, and myelosuppression, were compared in the two groups. Three‐year local progression free survival (LPFS) rates were determined using the Kaplan–Meier method and compared using the log‐rank test. Results The median follow‐up time was 39.7 months (range 24.3–61.3 months). Toxicities rates did not differ significantly in the HFRT‐SIB and HFRT‐SB groups, including rates of grade 2 skin toxicity (14.8% vs. 13.8%, p = 0.721), Grade 2 radiation pneumonia (2.8% vs. 3.6%, p = 0.355), grades 1, 2 and 3 myelosuppression (12.5%, 5.7% and 1.1%, respectively, vs. 9.6%, 7.8%, and 1.2%, respectively; p = 0.744). Three‐year cumulative LPFS rates were similar in the HFRT‐SIB and HFRT‐SB groups (99.3% vs. 98.6%, p = 0.52). Regional nodal recurrences were observed in one patient in the HFRT‐SIB group (after 27.4 months) and in two patients in the HFRT‐SB group (after 29.4 and 56.4 months), and a local recurrence was observed in one patient in the latter group after 36.0 months. One patient in the HFRT‐SIB group was diagnosed with distant metastases to bone, and one patient in the HFRT‐SB group was diagnosed with distant metastases to the liver. Conclusion Similar efficacy and safety of HFRT‐SIB and HFRT‐SB after breast‐conserving surgery in patients with early‐stage (T1‐2N0‐1) breast cancer. Longer‐term follow‐up is required to further compare their efficacy.https://doi.org/10.1002/cam4.70630breast‐conserving surgeryhypofractionatedradiotherapysequentialsimultaneous |
| spellingShingle | Na Li Yang Zhou Jianting Wang Yuwei Wang Ruiyu Shao Haifang Yang Wei Xiong Xuan Zheng Xiaohong Wang Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving Surgery Cancer Medicine breast‐conserving surgery hypofractionated radiotherapy sequential simultaneous |
| title | Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving Surgery |
| title_full | Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving Surgery |
| title_fullStr | Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving Surgery |
| title_full_unstemmed | Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving Surgery |
| title_short | Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost After Breast‐Conserving Surgery |
| title_sort | efficacy and safety of hypofractionated radiotherapy with a simultaneous integrated boost and with a sequential boost after breast conserving surgery |
| topic | breast‐conserving surgery hypofractionated radiotherapy sequential simultaneous |
| url | https://doi.org/10.1002/cam4.70630 |
| work_keys_str_mv | AT nali efficacyandsafetyofhypofractionatedradiotherapywithasimultaneousintegratedboostandwithasequentialboostafterbreastconservingsurgery AT yangzhou efficacyandsafetyofhypofractionatedradiotherapywithasimultaneousintegratedboostandwithasequentialboostafterbreastconservingsurgery AT jiantingwang efficacyandsafetyofhypofractionatedradiotherapywithasimultaneousintegratedboostandwithasequentialboostafterbreastconservingsurgery AT yuweiwang efficacyandsafetyofhypofractionatedradiotherapywithasimultaneousintegratedboostandwithasequentialboostafterbreastconservingsurgery AT ruiyushao efficacyandsafetyofhypofractionatedradiotherapywithasimultaneousintegratedboostandwithasequentialboostafterbreastconservingsurgery AT haifangyang efficacyandsafetyofhypofractionatedradiotherapywithasimultaneousintegratedboostandwithasequentialboostafterbreastconservingsurgery AT weixiong efficacyandsafetyofhypofractionatedradiotherapywithasimultaneousintegratedboostandwithasequentialboostafterbreastconservingsurgery AT xuanzheng efficacyandsafetyofhypofractionatedradiotherapywithasimultaneousintegratedboostandwithasequentialboostafterbreastconservingsurgery AT xiaohongwang efficacyandsafetyofhypofractionatedradiotherapywithasimultaneousintegratedboostandwithasequentialboostafterbreastconservingsurgery |